Adverse event totals18

The totals the trial posted for each group.

1 to 18 of 18

Total	Group	Affected	At risk
Total, all-cause mortality	Lanadelumab + SoC	8	28
Total, all-cause mortality	Lanadelumab Placebo + SoC	1	1
Total, all-cause mortality	Apremilast + SoC	37	194
Total, all-cause mortality	Apremilast Placebo + SoC	35	184
Total, all-cause mortality	Zilucoplan + SoC	20	100
Total, all-cause mortality	Zilucoplan Placebo + SoC	3	8
Total, other adverse events	Lanadelumab + SoC	12	27
Total, other adverse events	Lanadelumab Placebo + SoC	1	1
Total, other adverse events	Apremilast + SoC	63	189
Total, other adverse events	Apremilast Placebo + SoC	50	182
Total, other adverse events	Zilucoplan + SoC	46	95
Total, other adverse events	Zilucoplan Placebo + SoC	4	7
Total, serious adverse events	Lanadelumab + SoC	11	27
Total, serious adverse events	Lanadelumab Placebo + SoC	1	1
Total, serious adverse events	Apremilast + SoC	51	189
Total, serious adverse events	Apremilast Placebo + SoC	55	182
Total, serious adverse events	Zilucoplan + SoC	31	95
Total, serious adverse events	Zilucoplan Placebo + SoC	2	7

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04590586/event-totals